• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Pregnancy and Postpartum Course
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Access Purchased Content
Home » Blogs » The Carlat Psychiatry Blog » Switching Antidepressants: Direct Switch vs. Cross Taper (Med Fact Book Mini-Series, Part 2)

The Carlat Psychiatry Blog
The Carlat Psychiatry Blog RSS FeedRSS

General Psychiatry

Switching Antidepressants: Direct Switch vs. Cross Taper (Med Fact Book Mini-Series, Part 2)

November 4, 2025
Daniel Carlat, MD

Switching antidepressants isn’t hard.

Unless you rush it—or forget the exceptions.

This is Part 2 in my A to Z mini-series from the upcoming 8th edition of the Med Fact Book.

Today: Antidepressants.There are two basic ways to switch antidepressants (or any class of meds):

Direct switch and cross taper.

▸ Direct switch means stopping one medication and starting the next the very next day. 

→ Day 1: Drug A. Day 2: Stop Drug A, start Drug B. 

→ Example: sertraline to citalopram.

▸ Cross taper means gradually lowering the dose of one while slowly introducing the other. 

→ Day 1: Drug A. Day 2: Lower Drug A, add low dose of Drug B. Continue overlap with dose adjustments over 2–4 weeks, until you end up with Drug B only. 

→ Example: paroxetine to vortioxetine.

Here’s how I think about it:

▸ Direct switch (no overlap or taper) Use when meds have similar mechanisms and low interaction risk.

→ Sertraline to citalopram — fine to switch overnight.

→ Venlafaxine to duloxetine — usually okay directly, especially at moderate doses (e.g., venlafaxine 75–150 mg).

→ Sertraline to duloxetine or venlafaxine — often safe as a direct switch; start low and monitor closely.

→ SSRI to mirtazapine — generally safe to stop one and start the other the next day. May even help with sleep and appetite during the transition.

▸ Cross taper (gradual overlap) Use when switching drug classes or when interaction risks are higher.

→ Paroxetine to vortioxetine — taper paroxetine over 2–4 weeks while building vortioxetine.

→ Fluoxetine to bupropion — taper fluoxetine first to avoid higher bupropion levels and seizure risk.

→ Fluoxetine to nortriptyline — cross taper to avoid metabolic inhibition.

→ Sertraline to MAOI — stop sertraline, wait 2 weeks (5 weeks for fluoxetine), then start MAOI.

→ MAOI to new antidepressant — same: 2-week washout before switching.

▸ Discontinuation risk

→ Paroxetine, venlafaxine— high risk of withdrawal; taper slowly.

→ Bupropion, mirtazapine — lower risk; faster taper is usually fine.

→ Fluoxetine — long half-life; often no taper needed.These aren’t comprehensive rules—just reliable shortcuts for the most common situations.Adjust to the patient, not the protocol.

Next up: Antipsychotics—and when not to cross taper.

▸ Follow me (Daniel Carlat, MD) for grounded clinical tips from the Med Fact Book 

▸ What’s the antidepressant switch that still gives you pause?

Join the conversation on LinkedIn with Dr. Carlat. 

Carlat Total Access Subscriptions: Get access to every article on the website.

Complete access to every article you search on the website.

Shop for Total Access
Free Psychiatry Updates
The latest unbiased psychiatric information sent to your inbox.
Specify Your Interests
Featured Book
  • PB5e_3DCover.png

    Psychiatry Practice Boosters, Fifth Edition (2026)

    This fifth edition teaches you the key points of 66 of the most clinically relevant studies in...
    READ MORE
Featured Video
  • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
    General Psychiatry

    KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

    Read More
Featured Podcast
  • shutterstock_2697712297.jpg
    General Psychiatry

    How to Explain TMS

    Listen now
Recommended
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report
  • The Carlat Psychotherapy Report

Contact

carlat@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.